Viking Therapeutics Inc (NASDAQ:VKTX) — Market Cap & Net Worth
Market Cap & Net Worth: Viking Therapeutics Inc (VKTX)
Viking Therapeutics Inc (NASDAQ:VKTX) has a market capitalization of $3.35 Billion ($3.35 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4606 globally and #1490 in its home market, demonstrating a -8.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Viking Therapeutics Inc's stock price $30.00 by its total outstanding shares 115554295 (115.55 Million). Analyse VKTX cash flow conversion to see how efficiently the company converts income to cash.
Viking Therapeutics Inc Market Cap History: 2015 to 2026
Viking Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $394.04 Million to $3.47 Billion (16.12% CAGR).
Index Memberships
Viking Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.14% | #104 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.01% | #497 of 3165 |
Weight: Viking Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Viking Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Viking Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
49672.91x
Viking Therapeutics Inc's market cap is 49672.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $650.57 Million | $10.73K | -$39.49 Million | 60625.35x | N/A |
| 2021 | $531.55 Million | $10.70K | -$54.99 Million | 49672.91x | N/A |
Competitor Companies of VKTX by Market Capitalization
Companies near Viking Therapeutics Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Viking Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Viking Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Viking Therapeutics Inc's market cap moved from $394.04 Million to $ 3.47 Billion, with a yearly change of 16.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.47 Billion | -14.72% |
| 2025 | $4.07 Billion | -12.57% |
| 2024 | $4.65 Billion | +116.23% |
| 2023 | $2.15 Billion | +97.98% |
| 2022 | $1.09 Billion | +104.35% |
| 2021 | $531.55 Million | -18.29% |
| 2020 | $650.57 Million | -29.80% |
| 2019 | $926.75 Million | +4.84% |
| 2018 | $883.99 Million | +88.42% |
| 2017 | $469.15 Million | +241.18% |
| 2016 | $137.51 Million | -65.10% |
| 2015 | $394.04 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Viking Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.35 Billion USD |
| MoneyControl | $3.35 Billion USD |
| MarketWatch | $3.35 Billion USD |
| marketcap.company | $3.35 Billion USD |
| Reuters | $3.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more